- Home
- KLRS vs QXL Comparison
KLRS vs QXL Comparison
Compare KLRS & QXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | QXL |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 75.6M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KLRS | QXL |
|---|---|---|
| Price | $2.93 | $5.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 52.1K | ★ 76.7K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.70 | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | $165,000.00 | ★ $26,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $51.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $4.05 |
| 52 Week High | $11.88 | $7.70 |
Technical Indicators
Market Signals| Indicator | KLRS | QXL |
|---|---|---|
| Relative Strength Index (RSI) | 25.18 | 50.04 |
| Support Level | N/A | $4.13 |
| Resistance Level | $4.37 | $5.18 |
| Average True Range (ATR) | 0.19 | 0.44 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 3.03 | 39.90 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About QXL Quantum X Labs Inc. Common Stock
Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.